Key facts
- It has raised $2.4M; the latest was Early Stage VC ($2.4M) in Feb 2026.
- Notable investors include Clave (Pamplona), Grit Female Accelerator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for D-Sight (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for D-Sight (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About D-Sight (Biotechnology)
Operator of a biotech company intended to develop innovative neuroprotective treatments that prevent vision loss from retinal neurodegenerative diseases. The company offers neuroprotective eye drops designed to treat retinal diseases at their earliest stages, enabling customers to preserve vision through a non-invasive approach that targets the underlying neurodegeneration.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2023
- Employees
- 2
- Website
- dsight.es/
- Ownership
- Privately Held (backing)
D-Sight (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in D-Sight (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on D-Sight (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.